Avtor/Urednik		Kristl, Jernej
Naslov		Rekombinantni človeški proteini - nov nabor učinkovin za zdravljenje luskavice
Prevedeni naslov		Recombinant human proteins - new paltte of drugs for the treatment of psoriasis
Tip		članek
Vir		Med Razgl
Vol. in št.		Letnik 44, št. 2
Leto izdaje		2005
Obseg		str. 171-82
Jezik		slo
Abstrakt		Psoriasis is a chronic, inflammatory disease, which is estimated to affect 2,5 % of the world's population. Clinically it is characterized by thickened, silvery white, scaly plaques, that can produce considerable discomfort and pain in patients. For the treatment of psoriasis are currently mainly used corticosteroids, vitamin D analogs, ultraviolet A radiation and retinoids, all of which are nonspecific and unable to block the outbreak of disease. Advances in recombinant DNA technology and increased understanding of the pathophysiology of psoriasis have led to the development of numerous immunomodulatory drugs, which specifically inhibit the occurrence of disease. Novel agents have direct effect on T cell, T cell activation, T cell migration, and expression of inflammatory mediators. However, they can still not assure total remission, but offer enhanced efficacy and improved safety. We have to take into consideration that treatment of psoriasis is usually longterm, meaning that adverse effects of a drug represent a limiting factor for using that drug. In this article, known facts on psoriasis are presented, along with the review of therapies with stress on new immunomodulatory agents.
Izvleček		Luskavica je kronična vnetna bolezen, ki prizadene približno 2,5 % svetovnega prebivalstva. Klinično se kaže z odebeljenimi, srebrno-belimi in luskastimi žarišči na koži, ki lahko pri bolniku povzročijo hudo nelagodje in bolečino. Za zdravljenje luskavice se večinoma uporabljajo, kortikosteroidi, analogi vitamina D, obsevanje z ultravijolično A-svetlobo, retinoidi, vendar so obstoječi načini zdravljenja nespecifični in le zavirajo mehanizme njenega nastanka. Napredek rekombinantne DNA-tehnologije in boljše poznavanje patofiziologije luskavice sta botrovala razvoju številnih imunomodulacijskih beljakovinskih učinkovin, ki specifično zavirajo nastanek luskavice. Biološke učinkovine delujejo z neposrednim vplivom na limfocite T, njihovo aktivacijo, migracijo ter izražanje vnetnih mediatorjev. Kljub vsemu ozdravljenja ne zagotovijo, vendar učinkoviteje lajšajo njene bolezenske znake, poleg tega so vedno bolj varna. Upoštevati moramo namreč, da je zdravljenje luskavice navadno dolgotrajno, med katerim je prisotnost neželenih učinkov pri večini učinkovin omejitveni dejavnik. V tem članku so predstavljena znana dejstva o luskavici, v nadaljevanju pa sledi pregled učinkovin za njeno zdravljenje s poudarkom na novejših imunomodulacijskih učinkovinah.
Deskriptorji		PSORIASIS CYTOKINES ANTIBODIES, MONOCLONAL RECOMBINANT PROTEINS